Retatrutide Weight Loss: Results, Timeline & What to Expect

Retatrutide weight loss results from clinical trials are unlike anything previously recorded for a pharmaceutical treatment. A Phase 3 trial reported an average of 28.7% body weight loss (roughly 71 pounds) in 68 weeks. A number like that raises an obvious question: what does it actually mean for you?

The sections below cover Phase 3 and Phase 2 trial data, a month-by-month timeline of what weight loss looks like in practice, how results compare to tirzepatide and semaglutide, and the factors that determine where you personally land in the range. For the full dose-response tables and detailed trial methodology, see our retatrutide results article. If you want to start from the beginning, the retatrutide hub covers mechanism, dosing, and availability in one place.

Retatrutide is a triple agonist: it activates the GLP-1, GIP, and glucagon receptors simultaneously. GLP-1 suppresses appetite and slows gastric emptying. GIP enhances insulin sensitivity and fat metabolism. Glucagon increases energy expenditure and promotes lipolysis, the breakdown of stored fat. Each pathway adds a layer of effect, which is why the weight loss figures sit above anything a single or dual agonist has produced. That mechanism matters when interpreting the numbers below.

Retatrutide simultaneously activates three receptor pathways — GLP-1, GIP, and glucagon — producing additive metabolic effects no single or dual agonist achieves alone.

Phase 3 results: what TRIUMPH-4 showed

In December 2025, Eli Lilly released top-line results from TRIUMPH-4, the first Phase 3 retatrutide trial to report outcomes. The trial enrolled 445 participants with obesity (BMI ≥27) who also had moderate-to-severe knee osteoarthritis. All participants received weekly subcutaneous injections of retatrutide at 9mg or 12mg, or placebo, for 68 weeks.

TRIUMPH-4 weight loss results at 68 weeks

The 23.7% of participants who lost ≥35% of their body weight is historically unprecedented for any pharmaceutical treatment. For context, gastric bypass surgery typically produces 25–35% weight loss over a comparable timeframe. At the 9mg dose, 58.6% of participants lost ≥25% of their body weight.

Discontinuation rates in TRIUMPH-4

12.2% of participants on 9mg and 18.2% on 12mg discontinued treatment due to adverse events, versus 4.0% on placebo. Lilly reported that these discontinuations were "highly correlated with baseline BMI and included discontinuations for perceived excessive weight loss," without saying how many. That's an unusual finding for any obesity drug. In participants with a baseline BMI of 35 or higher, the rates were 8.8% (9mg) and 12.1% (12mg) versus 4.8% on placebo. For a complete side effects breakdown, see our retatrutide side effects guide.

The TRIUMPH-4 discontinuation rate is relevant context for expectation-setting. The rate was lower in TRIUMPH-1 (Jastreboff et al., NEJM 2026; adults with obesity or overweight without diabetes): 4.1%, 6.5% and 11.2% stopped due to adverse events at 4, 9 and 12mg versus 4.6% on placebo. In TRIUMPH-2 (adults with obesity or overweight and type 2 diabetes), permanent discontinuation due to adverse events or death was 4%, 12% and 8% versus 5%, so the 9mg rate was about the same as in TRIUMPH-4.

Phase 2 results: the clinical foundation

The Phase 2 trial, published in the New England Journal of Medicine in June 2023, remains the most detailed dataset available, and the primary source for dose-specific results at doses below 9mg. The trial enrolled 338 adults with obesity (BMI ≥30, or ≥27 with comorbidities). Average baseline weight was 109 kg (240 lbs), average BMI was 38.8, roughly 52% were men. Duration: 48 weeks, with lifestyle counseling including a 500 kcal/day dietary deficit and ≥150 minutes of exercise per week.

Phase 2 weight loss by dose at 48 weeks

At 12mg, 100% of participants achieved ≥5% weight loss and 83% achieved ≥15% weight loss, thresholds considered clinically meaningful in obesity medicine. The 8mg dose also achieved 100% ≥5% weight loss, with 77% hitting ≥15%. Even the 4mg dose produced more than 17% average weight loss.

The Phase 2 trial also included a meta-analysis benchmark: a 2025 systematic review and meta-analysis of 3 RCTs involving 878 patients found a mean body weight reduction of −14.33% versus placebo, with a BMI reduction of −5.38 and waist circumference reduction of −10.51 cm. The meta-analysis spans across doses, which is why it sits lower than the individual high-dose results.

Your weight loss timeline: month by month

One of the most practical questions people ask when starting retatrutide: when will I see results? The answer depends on your dose escalation schedule, but the Phase 2 data provides a reliable roadmap. The standard titration protocol starts at 2mg and escalates every 4 weeks, reaching 4mg, 8mg, and 12mg maintenance over 3–6 months.

The fastest weight loss happens during the titration phase, roughly months 3 through 6, when you're moving through the escalation schedule. After reaching your maintenance dose, the rate slows as your body adapts, but loss continues. That's the core difference from most other obesity drugs, where a clear plateau typically emerges.

Weight loss timeline on retatrutide 12mg (Phase 2 data)

Weight loss progression on retatrutide 12mg: dose escalation milestones mapped against cumulative body weight reduction through 48 weeks (Phase 2) and 68 weeks (TRIUMPH-4).

What the timeline looks like in practice

Months 1–2 are primarily about tolerability, not results. The 2mg starting dose is below therapeutic range; it exists to let your GI system adapt. You'll likely notice reduced appetite before you see significant scale movement. Expect 2–5 lbs of early loss, some of it water weight.

The rate accelerates between months 2 and 6. As you step through the 4mg and 8mg dose levels, appetite suppression intensifies, energy expenditure increases, and fat loss velocity picks up. This is typically when people around you start noticing. Clothes fit differently around month 3–4.

From month 6 onward at maintenance dose, the rate slows but doesn't stop. The Phase 2 data showed continued downward trending at 48 weeks, and the Phase 3 data confirmed that continued through 68 weeks. How much further it would go with extended treatment is not yet known from published data.

How retatrutide compares to tirzepatide and semaglutide

Cross-trial weight loss comparison

What network meta-analyses show

Two independent network meta-analyses published in 2025 attempt to compare these drugs more rigorously. A 2025 network meta-analysis (PMC12544991) found retatrutide produced −16.34 kg absolute weight loss versus placebo, compared with −11.82 kg for tirzepatide. A separate systematic review of 26 RCTs involving 15,491 participants found placebo-adjusted weight loss of approximately 22% for retatrutide 12mg, 18% for tirzepatide 15mg, and 14% for semaglutide 2.4mg, an effect-size hierarchy consistent across analyses.

The gap between retatrutide and tirzepatide is smaller in these meta-analyses than the raw trial numbers suggest, partly because the trials differ in duration and population characteristics. That said, the glucagon receptor, retatrutide's distinguishing feature, appears to add meaningful additional weight loss beyond what GLP-1 plus GIP achieves alone. The mechanistic rationale is sound: glucagon-driven lipolysis and energy expenditure increase act through pathways that GIP and GLP-1 do not fully activate.

Fat mass percentage results from a 2023 ADA comparative metabolic analysis show a close race at the fat mass level: retatrutide −17.5% fat mass, tirzepatide −17.2%, semaglutide −14.3% (all Phase 2, percentage of fat mass, not total body weight). The differences in total body weight loss partly reflect retatrutide's greater effect on non-fat metabolic factors, including energy expenditure.

What affects your individual results

The trial averages tell you what's possible at a population level. Your individual result will sit somewhere in a range, shaped by factors you can and can't control. Understanding these helps set realistic expectations and shows where you can actually influence the outcome.

Factors with the most impact

Body composition: what are you actually losing?

The scale weight you lose on retatrutide is not all fat. DEXA scan data from the Phase 2 trial provides a detailed breakdown of what actually came off, and it's a meaningful number to understand before you start, particularly if preserving muscle mass is a priority.

DEXA scan results at 48 weeks (12mg group, Phase 2)

The 74% fat / 26% lean mass split is comparable to what has been observed with tirzepatide and semaglutide in similar DEXA analyses. GLP-1 class medications do not selectively preserve lean mass; some muscle loss is expected with significant calorie restriction regardless of the drug used. The proportion of lean mass lost does not appear to be worse with retatrutide than with other GLP-1 class treatments.

Losing 26% lean mass still represents meaningful muscle loss in absolute terms for most people, roughly 13 lbs at the 12mg dose in Phase 2 conditions. Resistance training and adequate protein intake (typically 1.2–1.6g/kg of body weight per day) are the two most effective interventions for preserving lean mass during significant weight loss.

Visceral fat and liver fat

Retatrutide produces particularly pronounced reductions in visceral fat (the metabolically dangerous fat stored around internal organs) and liver fat. In a 2023 ADA presentation covering Phase 2 data, more than 85% of subjects with MASLD (metabolic dysfunction-associated steatotic liver disease) achieved steatosis resolution at the highest dose. Visceral fat reduction matters beyond the scale number; it drives the cardiometabolic improvements described in the section below.

Trial results vs real-world expectations

Clinical trial results are systematically better than real-world outcomes for several reasons. Participants are selected (they meet strict inclusion criteria), monitored closely, receive regular counselling, and have high adherence rates. In Phase 2, everyone received structured dietary guidance: a 500 kcal/day deficit and ≥150 minutes of exercise per week, which most people starting retatrutide independently will not replicate to the same degree.

A realistic framework for what to expect outside a trial setting:

For many people, even 10–15% weight loss produces substantial improvements in blood pressure, blood sugar, sleep quality, joint pain, and overall metabolic health. The headline 28.7% figure is real, but it comes from optimal conditions with a specific population. Setting expectations at 15–22% over 12–18 months is both achievable and clinically meaningful for most people starting at therapeutic doses.

What happens when you stop

There is no long-term retatrutide maintenance data yet: the drug is still in trials. Based on patterns from tirzepatide (SURMOUNT-4) and semaglutide (STEP-4), weight regain after stopping GLP-1 class medications is expected. In the tirzepatide withdrawal trial, participants who stopped after achieving ~21% weight loss regained approximately 14% of their original body weight within one year.

The underlying biology doesn't change when you stop: hunger hormones return to pre-treatment levels, energy expenditure decreases, and appetite rebounds. This is why obesity medicine specialists increasingly view these drugs as long-term treatments for a chronic condition, not as short-course interventions. If you're considering retatrutide, building a plan for long-term use or a defined maintenance strategy from the outset is worth discussing with your prescriber.

Side effects and what they mean for your results

GI side effects are the most common adverse events with retatrutide, and discontinuation is the primary reason real-world results fall short of trial outcomes. Understanding what to expect, and how to manage it, directly affects how much weight you lose.

Most common side effects (Phase 2 data)

The GI side effect profile is similar to tirzepatide and semaglutide. Cross-trial comparisons are rough (separate trials, different populations and durations, and no head-to-head retatrutide trial has reported), but nausea at 12mg in Phase 3 TRIUMPH-1 (42.4%, adults without diabetes) sits above the Zepbound label's 28% at 15mg and close to the Wegovy label's 44%. Most side effects peak during dose escalation and improve significantly once you stabilise at a maintenance dose.

Management strategies that keep you on track

• Slow your titration: Extending each dose level from 4 to 6–8 weeks before escalating gives the GI tract more adaptation time. There is no rule requiring a 4-week schedule. The dosing guide covers conservative protocols in detail.
• Eat smaller, more frequent meals: Large meals against a slowed stomach is the primary nausea trigger. Spreading the same calorie intake across 4–5 smaller meals can eliminate most injection-day nausea.
• Avoid high-fat meals around injection day: Fatty foods slow gastric emptying further. Keeping the 24–48 hours post-injection lower in fat is one of the most practical management tools.
• Stay hydrated: Dehydration worsens GI symptoms across all GLP-1 class medications. Electrolytes matter, particularly potassium and sodium, if diarrhoea or reduced food intake is present.
• Consider microdosing: Splitting the weekly dose into smaller, more frequent injections reduces peak plasma concentrations and may reduce side effects, though no trial has tested this. See our microdosing retatrutide guide for protocols.

For a complete side effects breakdown including injection site reactions, cardiac findings, and when to pause titration, see our retatrutide side effects guide. Managing side effects effectively has a bigger impact on your results than almost anything else.